Brooks Laboratories Limited (BROOKS.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-153.4%

-₹34.89

vs ₹65.36 price

Levered DCF

-₹72.18

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

—

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	4.44×	-33.66×	-12.8×	-7.44×	-9.42×	-7.89×	-1.11×	-6.67×
P/B	0.89×	3.42×	3.82×	2.1×	2.08×	1.93×	0.28×	0.94×
P/S	1.27×	4.06×	3.16×	2.49×	1.99×	1.98×	0.39×	1.8×
EV / EBITDA	4.08×	58.68×	61.42×	-5.55×	-15.2×	146.48×	-15.46×	-23.25×
Gross margin	21.0%	16.9%	28.3%	20.2%	-8.7%	28.3%	22.6%	17.4%
Operating margin	6.4%	4.0%	1.5%	-11.0%	8.5%	-14.1%	-13.0%	-21.8%
Net margin	28.7%	-12.1%	-24.6%	-33.5%	-21.2%	-25.1%	-35.3%	-26.9%
Current ratio	1.72×	1.48×	1.35×	0.83×	1.25×	0.75×	0.83×	0.67×
Debt / equity	0.07×	0.08×	0.09×	0.09×	0.29×	0.4×	0.28×	0.3×
Interest coverage	6.55×	3.25×	1.42×	-3.16×	2.5×	-3.5×	-2.68×	-4.05×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	20.0%	-10.2%	-29.9%	-28.3%	-22.1%	-24.5%	-24.8%	-14.1%
Return on invested capital	4.1%	3.1%	1.6%	-6.8%	3.9%	-9.4%	-7.0%	-8.6%
Return on assets	16.6%	-8.1%	-21.7%	-19.1%	-9.9%	-12.0%	-15.4%	-8.8%
Free cash flow yield	4.7%	-0.0%	-4.0%	-9.6%	-35.8%	-0.8%	-44.1%	-6.0%
Earnings yield	22.5%	-3.0%	-7.8%	-13.4%	-10.6%	-12.7%	-89.9%	-15.0%
Enterprise value	₹1.1B	₹3.4B	₹2.6B	₹1.6B	₹2B	₹1.8B	₹543.6M	₹1.3B
Net debt / EBITDA	0.04×	1.09×	1.32×	-0.22×	-1.68×	24.36×	-7.75×	-5.23×
Cash conversion cycle (days)	66	65	46	-11	74	17	1	-59